GSD NovaType II allows for the qualitative detection and discrimination of relevant mutations associated with SARS-CoV-2 variants: B.1.1.7 (UK), B.1.351 (South Africa), and B.1.1.28 (P.1) (Brazil). This assay is intended as a confirmatory test for potential mutants and should only be performed after first testing patient specimens for the presence of SARS-CoV-2 RNA with a CE-IVD marked screening assay such as the GSD NovaPrime® SARS-CoV-2 (COVID-19) RT-PCR kit.
Copyright ©2020 Design & Developed by GuzelArt